Carl Sofley, MD
Internal Medicine · Anderson, SCNPI 1316940059
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Novo Nordisk AS at 54.2% of the total. Reporting peaked in 2019 at $10,412 and has fallen 78.2% since, to $2,267 in 2025. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 453 payments — averaging $37.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$9K
- Novo Nordisk$940
- Lilly USA, LLC$802
- Novartis$730
- Janssen Research & Development, LLC$712
- AbbVie$553
- plus $4K from 36 others
Across 286 payments — averaging $2297.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$295K
- Eli Lilly$115K
- Janssen Research & Development, LLC$114K
- Abbott$51K
- Esperion Therapeutics, Inc.$32K
- Sanofi US Services Inc.$30K
- plus $19K from 4 others
What the payments were for
- Travel & lodging$9,61056%
- Food & beverage$7,52044%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,144 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 281 | $246,914 |
| OzempicSemaglutide | 159 | $220,455 |
| JardianceEmpagliflozin | 151 | $164,319 |
| FarxigaDapagliflozin Propanediol | 105 | $99,019 |
| MounjaroTirzepatide | 61 | $89,496 |
| TrulicityDulaglutide | 49 | $81,342 |
| JanuviaSitagliptin Phosphate | 64 | $55,896 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $51,391 |
| LinzessLinaclotide | 49 | $44,961 |
| MyrbetriqMirabegron | 72 | $43,309 |
| Repatha SureclickEvolocumab | 33 | $42,233 |
| XareltoRivaroxaban | 33 | $33,547 |
| RexultiBrexpiprazole | 23 | $32,482 |
| RybelsusSemaglutide | 18 | $31,370 |
| EntrestoSacubitril/Valsartan | 19 | $26,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $940 | $251,825177 claims |
| PfizerEliquis | $535 | $246,914281 claims |
| Boehringer IngelheimJardiance, Tradjenta | $137 | $186,000175 claims |
| Lilly USA, LLCMounjaro, Trulicity | $802 | $170,838110 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $499 | $137,711169 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $272 | $77,872108 claims |
| MerckJanuvia | $30 | $55,89664 claims |
| AbbVieLinzess, Synthroid | $553 | $49,277106 claims |
| Johnson & JohnsonXarelto, Invokana | $43 | $46,87958 claims |
| Astellas Pharma US IncMyrbetriq | $91 | $43,30972 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $247 | $32,48223 claims |
| NovartisEntresto | $730 | $26,38519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Anderson
- Anita VagnoniAnderson$21K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
- Bruce GrayGreenville$111K
- Leonard AlsfeldCharleston$91K
- Edward Botse-BaidooMyrtle Beach$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.